Consortium Therapeutic Studies of Primary Central Nervi*

描述（由申请人提供）：UCLA神经肿瘤学项目将作为“成员机构”参加北美脑肿瘤联盟（NABTC）的临床试验。NABTC的成员机构还包括威斯康星大学、匹兹堡大学、达纳法伯癌症中心、安德森癌症中心、美国国立卫生研究院神经肿瘤科、加州大学旧金山分校、纪念斯隆凯特琳癌症中心和德克萨斯大学圣安东尼奥分校的药代动力学中心。加州大学旧金山分校将担任NABTC的牵头机构，普拉多斯博士将担任NABTC的组长。该资助的重点将是对治疗成人原发性中枢神经系统恶性肿瘤，特别是多形性胶质母细胞瘤和其他高级别胶质瘤的有前景的新治疗药物或方法进行I期和II期临床评估。此外，我们将对中枢神经系统肿瘤生物学方面的潜在临床意义进行辅助实验室研究。加州大学洛杉矶分校将继续与NABTC合作，与联盟的其他成员和NCI合作，共同构思、创造和评估中枢神经系统肿瘤治疗的新方法。这将在很大程度上通过加州大学洛杉矶分校现有的环境和专业知识来实现，包括医师调查员、多学科方法、数据管理资源、患者群体、神经成像、手术和放射以及药物控制程序的专业知识和先进仪器。加州大学洛杉矶分校还将为多机构协议概念开发和协议执行提供有效的环境和专业知识。最后，加州大学洛杉矶分校拥有重要的基础设施专业知识，可以帮助该联盟满足加速脑癌转化研究的重要需求。

DESCRIPTION (provided by applicant): UCLA Neuro-Oncology Program will participate in the clinical trials of the North American Brain Tumor Consortium (NABTC) as a "Member Institution". Member Institutions of the NABTC will also include, the University of Wisconsin, the University of Pittsburgh, Dana Farber Cancer Center, M D Anderson Cancer Center, the Neuro-Oncology Branch at the National Institutes of Health, the University of California, San Francisco, Memorial Sloan Kettering Cancer Center and the Pharmacokinetics Center at the University of Texas San Antonio. UCSF will be the Lead Institution and Dr. Prados the Group Leader for the NABTC. The focus of this grant will be to perform phase I and II clinical evaluations of promising new therapeutic agents or approaches for the treatment of primary CNS malignancies in adult patients, especially glioblastoma multiforme and other high grade gliomas. Additionally, we will perform ancillary laboratory studies of aspects of CNS tumor biology with potential clinical implications. UCLA will continue to extend it ongoing work with NABTC by interacting with other members of the consortium and with NCI in a concerted way to conceive, create and evaluate new approaches to the therapy of CNS tumors. This will be largely achieved through the existing environment and expertise that exist at UCLA including physician investigators, multidisciplinary approach, data management resources, patient population, expertise and advanced instrumentation for neuroimaging, surgery and radiation, and drug control procedures. UCLA will also provide an effective environment and expertise for multi-institutional protocol concept development and protocol conduct. Finally, significant infrastructure expertise exists at UCLA to aide the consortium with needs that are important for the acceleration of brain cancer translational research.